PACIFIC: Quality of Life is maintained in NSCLC patients treated with durvalumab

In the randomised, double-blind phase III trial PACIFIC, durvalumab has shown to improve progression-free survival (PFS) while upholding quality of life measures in locally advanced, unresectable non-small cell lung cancer (NSCLC) patients (abstract PL 02.02). Dr. Rina Hui of the University of Sydney and Westmead Hospital in Australia presented these findings on Tuesday at the IASLC 18th WCLC in Yokohama.

Assessment of QoL

The researchers viewed patient-reported quality of life data as imperative to better informing the decision of whether or not to administer durvalumab in this patient population. The researchers randomized NSCLC patients who had received standard concurrent chemoradiation, but had not experienced disease progression, into two groups. The intervention group was treated with durvalumab for up to twelve months, while the control group was treated with placebo. Symptoms, function and global health status/QoL were evaluated using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 v3 questionnaire and its lung cancer module, QLQ-LC13. Patients completed the questionnaires at baseline, Week 4, Week 8, q8w until Week 48, then q12w until disease progression. Changes from baseline for key symptoms were analysed using a mixed model for repeated measures (MMRM). Time to deterioration (TTD) and odds of improvement were analysed. Deterioration or improvement was defined as a change in score from baseline ≥ 10. Hazard ratios (HR) were calculated using a stratified log-rank test and odds ratios (OR) using logistic regression.